Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Group 1 - The article discusses Delcath Systems (NASDAQ: DCTH) and its progress towards submitting a New Drug Application (NDA) for its melphalan drug/device kit, highlighting the company's efforts over the past three years [1] - The author emphasizes their long position in DCTH shares, indicating a personal investment interest in the company's future performance [2] - The article is part of a broader investment research service called Compounding Healthcare, which focuses on innovative healthcare companies and potential investment opportunities [1]